A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

NCT00551915 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

756

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections; Virus Diseases

Interventions

BIOLOGICAL: AR51 (12, 10)
BIOLOGICAL: PR51 (3, 10)
BIOLOGICAL: PR51 (6, 10)
BIOLOGICAL: PENTACEL™
BIOLOGICAL: RECOMBIVAX HB™

Sponsor

Merck Sharp & Dohme LLC